Dr. Binay Shah Delivers a Keynote Lecture at the 2023 Global Oncology Summit

By: BTF Staff

 

October 28, 2023 – Known for its unwavering commitment to improving access to cancer care in resource-poor communities, the Binaytara Foundation hosted its “2023 Global Oncology Summit.” Central to the event was a keynote speech by Dr. Binay Shah, President of the Binaytara Foundation, who shared profound insights on “infrastructure development,” drawing from extensive experience in establishing oncology programs in Nepal and India.

 

Pioneering Efforts in Infrastructure Development in Nepal:

 

Dr. Binay Shah’s address illuminated the audience on the challenges and triumphs of setting up robust medical infrastructure in resource-constrained regions. He detailed the Foundation’s instrumental role in supporting the establishment of a bone marrow transplant center at the Civil Service Hospital in Kathmandu, Nepal.

 

The Foundation sponsored the training of the transplant team, enabling them to undergo training in the United States and Sri Lanka. This strategic move ensured the team was well-equipped with international expertise and ready to deliver exceptional care to patients in Nepal. Beyond financial support, the Binaytara Foundation catalyzed a pivotal collaboration between the Civil Service Hospital and the University of Illinois Chicago (UIC). The bone marrow transplant center remains the only center for many patients with blood and bone marrow disorders in Nepal.

 

Furthermore, the Foundation operates a 25-bed cancer hospital boasting state-of-the-art digital infrastructure. Recognizing the pressing need for expanded facilities, the Foundation has embarked on an ambitious project to scale the hospital to accommodate 200 beds, aiming to serve a larger patient base and cater to the growing demand.

 

During the conference, Dr. Binay Shah expounded on their approach to infrastructure development. He emphasized the Foundation’s dual focus on both physical and digital infrastructure. “It’s not just about bricks and mortar; it’s about ensuring that our facilities are digitally advanced to provide seamless care, from diagnosis to treatment and beyond,” said Dr. Shah.

 

The Binaytara Foundation’s approach serves as a model for how philanthropic endeavors can lead to tangible, impactful results in improving access to healthcare in low and middle-income countries. By understanding the intricacies of both physical infrastructure and the digital landscape, they are setting the stage for a future where quality healthcare is accessible to all, irrespective of geographical or economic barriers.

 

Palliative Care in Madhya Pradesh:

 

Another hallmark of the Foundation’s efforts, as Dr. Shah highlighted, is its collaboration with the Government of Madhya Pradesh, India. BTF’s support has led to the establishment of palliative care programs in Madhya Pradesh. This initiative marks a significant stride towards providing holistic cancer care, ensuring that patients receive not only curative treatments but also support in managing pain and improving their quality of life.

 

Dr. Shah’s keynote was a powerful reminder of the change that can be achieved through collaboration, determination, and a genuine commitment to improving lives.

Taylor Pak

Recent Posts

ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC)

By: Tiantian Zhang1, Yiqun Han2, Lei Deng3 1. Department of Internal Medicine, University of Central…

5 months ago

ASCO24 LAURA Trial Summary

By: Zhiting Tang1, Lei Deng21. Unity Hospital, Rochester Regional Health, Rochester, NY2. University of Washington/Fred…

5 months ago

FDA Approves Tovorafenib for Pediatric Low-Grade Glioma With BRAF Mutation

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug…

6 months ago

FDA Approves Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 29, 2024, the U.S. Food and Drug…

6 months ago

FDA Approves Lutetium Lu 177 Dotatate for SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug…

6 months ago

FDA Approves Alectinib for Adjuvant Treatment in Non-Small Cell Lung Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 18, 2024, the U.S. Food and Drug…

6 months ago